Recombinant Erythropoietin Provides Protection against Renal Fibrosis in Adenine-Induced Chronic Kidney Disease
Authors:
- Yanet Gutiérrez-MercadoYGYanet Gutiérrez-Mercado
- Francisco Javier Gálvez-GastélumFGFrancisco Javier Gálvez-Gastélum
- Hugo Esquivel-SolísHugo Esquivel-Solís
- Claudia Morales-MartínezCMClaudia Morales-Martínez
- Alejandro A. Canales-AguirreAlejandro A. Canales-Aguirre
- Ana Laura Márquez-AguirreAMAna Laura Márquez-Aguirre
Open Access
- 27 February 2020
- journal article
- research article
- Published by Wiley in Mediators of Inflammation
- Vol. 2020, 1-11
Abstract
Chronic kidney disease (CKD) causes anemia by renal damage. In CKD, the kidney is submitted to hypoxia, persistent inflammation, leading to fibrosis and permanent loss of renal function. Human recombinant erythropoietin (rEPO) has been widely used to treat CKD-associated anemia and is known to possess organ-protective properties that are independent from its well-established hematopoietic effects. Nonhematopoietic effects of EPO are mediated by an alternative receptor that is proposed to consist of a heterocomplex between the erythropoietin receptor (EPOR) and the beta common receptor (βcR). The present study explored the effects of rEPO to prevent renal fibrosis in adenine-induced chronic kidney disease (Ad-CKD) and their association with the expression of the heterodimer EPOR/βcR. Male Wistar rats were randomized to control group (CTL), adenine-fed rats (Ad-CKD), and Ad-CKD with treatment of rEPO (1050 IU/kg, once weekly for 4 weeks). Ad-CKD rats exhibited anemia, uremia, decreased renal function, increased infiltration of inflammatory cells, tubular atrophy, and fibrosis. rEPO treatment not only corrected anemia but reduced uremia and partially improved renal function as well. In addition, we observed that rEPO diminishes tubular injury, prevents fibrosis deposition, and induces the EPOR/βcR heteroreceptor. The findings may explain the extrahematopoietic effects of rEPO in CKD and provide new strategies for the treatment of renal fibrosis in CKD.Keywords
Funding Information
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (CB-2014-01-243118)
This publication has 36 references indexed in Scilit:
- Dual Inhibiting Senescence and Epithelial-to-Mesenchymal Transition by Erythropoietin Preserve Tubular Epithelial Cell Regeneration and Ameliorate Renal Fibrosis in Unilateral Ureteral ObstructionBioMed Research International, 2013
- Adenine-induced chronic kidney and cardiovascular damage in ratsJournal of Pharmacological and Toxicological Methods, 2013
- Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptorKidney International, 2013
- Chronic Administration of Small Nonerythropoietic Peptide Sequence of Erythropoietin Effectively Ameliorates the Progression of Postmyocardial Infarction–Dilated CardiomyopathyThe Journal of Pharmacology and Experimental Therapeutics, 2013
- The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotectionMedical Science Monitor, 2013
- Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in miceJournal of Clinical Investigation, 2011
- Erythropoietin (EPO) in acute kidney injuryAnnals of Intensive Care, 2011
- miR-200a Prevents Renal Fibrogenesis Through Repression of TGF-β2 ExpressionDiabetes, 2010
- Common pathophysiological mechanisms of chronic kidney disease: Therapeutic perspectivesPharmacology & Therapeutics, 2010
- Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promiseKidney International, 2006